Allison DeAngelis,

Allison DeAngelis is a seasoned biotech reporter with extensive experience covering the drug industry and biopharma startups. She currently works at STAT, where she focuses on venture capital and biotech startups. Prior to joining STAT, Allison covered the drug industry for Insider and the Boston Business Journal. She was recognized as the Washington Newspaper Publishers Association's News Writer of the Year in 2016. Based in Boston, Allison's reporting encompasses a wide range of topics within the biotech and pharmaceutical sectors. In non-pandemic times, she also enjoys traveling internationally.

Biography:  https://www.statnews.com/staff/allison-deangelis/

99%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

100%

Examples:

No current examples available.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

100%

Examples:

No current examples available.

Deceptions

100%

Examples:

No current examples available.

Recent Articles

New Gene Therapies and Innovative Approaches: Advancing Treatments for Sickle Cell Disease

New Gene Therapies and Innovative Approaches: Advancing Treatments for Sickle Cell Disease

Broke On: Tuesday, 21 May 2024 Two new gene therapies for sickle cell disease, approved in fall 2023, offer hope for a functional cure but raise questions about accessibility and equity. Researchers also explore alternative treatments like stem cell transplants from umbilical cord blood and small molecules that modulate gene expression. The goal is to develop accessible, effective, and equitable treatments for sickle cell disease.